£160.00
59 in stock
For research use only — Not for human or animal use
At Futureproof Peptides, our Retatrutide 40mg vial is available for research use. Retatrutide is a research peptide studied in metabolic research for its interaction with multiple hormone receptors.
It is classified as a receptor agonist that targets pathways linked to glucagon receptor activity, glucagon like peptide-1 GLP-1, and glucose dependent insulinotropic polypeptide GIP.
Retatrutide has been explored in research settings to understand how it interacts with biological systems involved in weight management. Current interest in this peptide is linked to its multi-receptor activity and how it may influence signalling pathways associated with energy balance.
Clinical trials have examined retatrutide in the context of metabolic research. These studies have focused on how the peptide interacts with hormone receptors involved in appetite regulation, glucose metabolism, and energy use.
Research areas include:
Some clinical trials have explored the relationship between receptor agonist activity and weight loss outcomes in controlled environments. These findings are limited to research settings and are not established for clinical use.
Retatrutide is a receptor agonist that interacts with multiple hormone receptors. These include the glucagon receptor, GLP-1 pathways, and GIP signalling. These systems are involved in metabolic regulation and are commonly studied in metabolic research.
Research has examined:
This multi-target approach is of interest in research as it allows observation of how different hormone systems interact within the same model.
Current laboratory and clinical research on retatrutide includes:
These areas are still under investigation. Findings from clinical trials are used to support further research but are not conclusive for non-research use.
Some experimental reference administration at an injection site. These methods are limited to research environments and are not intended for clinical or therapeutic use.
This vial format differs from prefilled pen formats, as it allows controlled preparation and flexibility within research protocols.
Clinical trials have reported mild to moderate gastrointestinal effects in some research settings. These side effects are still being studied, and data remains limited to controlled environments.
Long term data on retatrutide is still under investigation. Current understanding is based on ongoing clinical trials and early stage research. As with other receptor agonist compounds, outcomes may vary depending on study design and model.
Our retatrutide 40mg vial is supplied as a lyophilised peptide powder. Reconstitution is required prior to use, typically using bacteriostatic water in laboratory settings.
Handling conditions such as temperature control and avoiding repeated freeze and thaw cycles are important for maintaining peptide stability.
Our retatrutide 40mg vial provides a higher content format for metabolic research focused on hormone receptors, weight management, and multi-pathway signalling models.
Disclaimer: This product is sold strictly for research purposes only. It is not intended for medical, cosmetic, or therapeutic use. Not for human consumption.
Discount Applied Successfully!
Your savings have been added to the cart.
